Efficacy of Sunitinib Rechallenge in Kidney Cancer: Are mTOR Inhibitors Involved or Is It Only a Matter of Time?

Publisher： Karger

E-ISSN： 2296-5262|34|6|295-296

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.34, Iss.6, 2011-05, pp. : 295-296

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Rechallenge with mTOR Inhibitors in Metastatic Renal Cell Carcinoma Patients Who Progressed on Previous mTOR Inhibitor Therapy

By  

Oncology, Vol. 85, Iss. 1, 2013-06 ,pp. : 8-13

Karger

Access to resources Recommend Favorite

Efficacy of Sunitinib Re-Exposure after Failure of an mTOR Inhibitor in Patients with Metastatic RCC

By  

Oncology Research and Treatment, Vol. 34, Iss. 6, 2011-05 ,pp. : 310-314

Karger

Access to resources Recommend Favorite

Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3390-3392

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2−/− mice

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 4, 2015-04 ,pp. : 1451-1463

John Wiley & Sons Inc

Access to resources Recommend Favorite

The mTOR Pathway in Breast Cancer

By Hynes Nancy   Boulay Anne  

Journal of Mammary Gland Biology and Neoplasia, Vol. 11, Iss. 1, 2006-01 ,pp. : 53-61

Springer Publishing Company

Access to resources Recommend Favorite